// App-Quantinova.ai

4520 : A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx).

Researchers

Presenter

  • Jianjun Gao

Principal Investigators

  • Nizar M. Tannir

  • Rebecca Slack

  • Kamran Ahrar

  • Priya Rao

  • Chaan S. Ng

  • Eric Jonasch

  • Matthew T. Campbell

  • Surena F. Matin

  • Amado J. Zurita

  • Jennifer Wang

  • Jorge M Blando

  • Hao Zhao

  • Luis M Vence

  • Sreyashi Basu

  • Hong Chen

  • James Patrick Allison

  • Christopher G. Wood

  • Padmanee Sharma

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Bevacizumab

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • NA

Study Id's

  • NCT02210117

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved